A Supplier's Role in Ensuring and Improving Excipient Quality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Supplier's Role in Ensuring and Improving Excipient Quality
Excipients are the hidden champions of drug development—no API works consistently without the right excipient. Pharmaceutical excipients, however, require stringent quality management. This article discusses how the supplier of pharmaceutical raw materials should take a central role in ensuring excipient quality.


Pharmaceutical Technology
Volume 35, pp. s36-s38

The way forward

Ongoing dialogue is crucial. In June 2011, Merck Millipore hosted its second Pharma-Forum in Darmstadt, Germany, which included discussions regarding new legal requirements for pharmaceutical excipients. Representatives from the pharmaceutical industry discussed ways to secure the supply chain, and updated attendees on the activities of Rx–360 and the development of inspection programs. A key message that came from the event was that the pharmaceutical industry will lose credibility if new cases of contamination or adulteration occur. In parallel, the sentiment of participants was that regulators may be at risk of losing control of the increasingly global and complex supply chain. It was agreed that an important solution to prevent harmful incidents lies with improving risk-management approaches to manufacturing and supply.

The event also included discussion of the EU Directive 2001/83/EC (15) in which the EU Commission gave a mandate to the European Directorate for the Quality of Medicines and HealthCare to establish a risk-based annual program for inspections. According to the directive, inspections are to be performed both inside and outside of Europe and will involve manufacturing sites and brokers/distributers holding certificates of suitability to European Pharmacopeia monographs. It is hoped that the inspections will help detect noncompliance and will result in necessary actions that may include withdrawal of the certificate. Overall, it was agreed that finished-product manufacturers must improve their ability to select GMP-compliant pharmaceutical ingredients suppliers and to audit/monitor them accordingly.

Conclusion

In the past, the risks associated with excipients were underestimated. However, the quality of excipients should match the quality expected for APIs. Excipients are the hidden champions in pharmaceutical drug formulation; no API would work consistently without the optimal excipient. Today, industry organizations and regulatory authorities are evolving toward more stringent regulations. Once common standards are agreed upon, these should provide a basis for improving drug quality and patient safety. In the absence of stringent regulatory practices and in light of the growing complexity and global length of supply chains, selecting the right excipient is vital.

Frithjof Holtz is head of regulatory experts/customer audits and Najib Sehat is director of regulatory and technical services, both at Merck KGaA, Frankfurter Str. 250, D 64293 Darmstadt, Germany,
,
.

References

1. S. Wolfgang, presentation at ExcipientFest Americas (Baltimore, MD, 2011).

2. FDA, "Advisory to Drug and Dietary Supplement Manufacturers, Compounding Pharmacies and Distributors of Excipients and Dietary Ingredients — FDA Detects High Levels of Peroxide in Crospovidone" Drug Safety Alert (Rockville, MD, Oct. 21, 2010).

3. H.R. 1483, 112th Congress, 1st Session (Washington, DC), amended April 12 2011.

4. EC Directive 2011/62/EU, Amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use, as Regards the Prevention of the Entry into the Legal Supply Chain of Falsified Medicinal Products (Brussels, June 2011).

5. USP 32–NF 27 <1078> "Good Manufacturing Practices for Bulk Pharmaceutical Excipients."

6. W. Bogdanich and J. Hooker, New York Times, May 6, 2007.

7. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2006).

8. IPEC Position Paper, Excipient Pedigree (2008).

9. EFCG, IPEC, European Association of Chemical Distributors and the Pharmaceutical Quality Group, "Certification Standards for Pharmaceutical Excipients: Good Manufacturing Practices, Good Distribution Practices" (March 2011).

10. Rx–360, "Rx–360 Update," http://www.rx-360.org/, accessed Aug. 4, 2011.

11. IPEC–PQG, Joint IPEC–PQG Good Manufacturing Practices Audit Guideline for Pharmaceutical Excipients (2008).

12. ICH, Q7 Harmonized Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).

13. Rx-360, Audit Guide for Basic Chemicals and Raw Materials (2010).

14. ICH, M4 Common Technical Document (1999).

15. EU Directive 2001/83/EC, Community Cod Relating to Medicinal Products for Human Use (Brussels, November 2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here